Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2026-08-11 16:21:36 ET · period of report 2026-08-08 · accession 0000897069-26-001602 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-11 16:21 | 2026-08-08 | PCSA | Ng George K | CEO, Dir | M - OptEx | — | +1,600 | 17.1K | +10% | — |
| D | 2026-08-11 16:21 | 2026-08-08 | PCSA | Ng George K | CEO, Dir | M - OptEx | $0.00 | -1,600 | 19.6K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-08 | M | A | 1,600 | — | 17,092 | D | — | — | (F1) Distribution of time-based service award. |
| 2 | Derivative | Restricted Stock | 2026-08-08 | M | D | 1,600 | $0.00 | 19,624 | D | $0.00 · — to — | 1,600 Common Stock | (F1) Distribution of time-based service award. (F1) Distribution of time-based service award. (F3) Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |